Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Cash from Operations: 2018-2024

Historic Cash from Operations for Stoke Therapeutics (STOK) over the last 7 years, with Dec 2024 value amounting to -$86.9 million.

  • Stoke Therapeutics' Cash from Operations fell 40.49% to -$30.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.8 million, marking a year-over-year increase of 162.68%. This contributed to the annual value of -$86.9 million for FY2024, which is 7.13% down from last year.
  • Per Stoke Therapeutics' latest filing, its Cash from Operations stood at -$86.9 million for FY2024, which was down 7.13% from -$81.1 million recorded in FY2023.
  • In the past 5 years, Stoke Therapeutics' Cash from Operations registered a high of -$31.9 million during FY2022, and its lowest value of -$86.9 million during FY2024.
  • Over the past 3 years, Stoke Therapeutics' median Cash from Operations value was -$81.1 million (recorded in 2023), while the average stood at -$66.6 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first surged by 52.37% in 2022, then tumbled by 154.40% in 2023.
  • Yearly analysis of 5 years shows Stoke Therapeutics' Cash from Operations stood at -$42.2 million in 2020, then slumped by 58.47% to -$66.9 million in 2021, then soared by 52.37% to -$31.9 million in 2022, then plummeted by 154.40% to -$81.1 million in 2023, then dropped by 7.13% to -$86.9 million in 2024.